MX2009012964A - Formulacion de peptido estable a alta temperatura. - Google Patents
Formulacion de peptido estable a alta temperatura.Info
- Publication number
- MX2009012964A MX2009012964A MX2009012964A MX2009012964A MX2009012964A MX 2009012964 A MX2009012964 A MX 2009012964A MX 2009012964 A MX2009012964 A MX 2009012964A MX 2009012964 A MX2009012964 A MX 2009012964A MX 2009012964 A MX2009012964 A MX 2009012964A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- stability
- lyophilized
- lyophilized product
- months
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94155607P | 2007-06-01 | 2007-06-01 | |
| US96908007P | 2007-08-30 | 2007-08-30 | |
| PCT/US2008/006898 WO2008150479A2 (en) | 2007-06-01 | 2008-05-29 | High temperature stable peptide formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012964A true MX2009012964A (es) | 2010-01-14 |
Family
ID=40094334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012964A MX2009012964A (es) | 2007-06-01 | 2008-05-29 | Formulacion de peptido estable a alta temperatura. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7879805B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2150537A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010530846A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008260483A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2687246A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009012964A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008150479A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| CN104490767A (zh) * | 2009-05-04 | 2015-04-08 | 艾伯维生物技术有限公司 | 人抗TNF-α抗体的稳定高蛋白质浓度制剂 |
| CA2781666C (en) * | 2009-11-23 | 2017-02-21 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
| ES2543795T3 (es) | 2010-03-31 | 2015-08-21 | Stabilitech Ltd. | Estabilización de partículas virales |
| DK2552478T3 (en) | 2010-03-31 | 2017-03-27 | Stabilitech Ltd | EXCIPIENTS FOR STABILIZING VIRUS PARTICLES |
| WO2011121305A2 (en) | 2010-03-31 | 2011-10-06 | Stabilitech Ltd. | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| MX355543B (es) | 2010-08-13 | 2018-04-20 | Aileron Therapeutics Inc Star | Macrociclos peptidomiméticos. |
| TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物 |
| CN102488886B (zh) * | 2011-09-26 | 2014-03-26 | 上海天伟生物制药有限公司 | 一种低杂质含量的卡泊芬净制剂及其制备方法和用途 |
| CN103386117B (zh) * | 2011-09-26 | 2015-09-30 | 上海天伟生物制药有限公司 | 一种低杂质含量的卡泊芬净制剂及其制备方法和用途 |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
| EP2773364A1 (en) * | 2011-11-02 | 2014-09-10 | The University of Chicago | Stable pharmaceutical formulations of growth factor peptides |
| JP6450191B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR20140138900A (ko) * | 2012-03-09 | 2014-12-04 | 온코세라피 사이언스 가부시키가이샤 | 펩티드를 포함한 의약 조성물 |
| JP6148487B2 (ja) * | 2012-05-31 | 2017-06-14 | 久保木 芳徳 | チタン−タンパク質複合体の製造方法 |
| EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US10251935B2 (en) * | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| LT3149048T (lt) | 2014-05-28 | 2020-05-11 | Nono Inc. | Tat-nr2b9c chlorido druska |
| WO2016049355A1 (en) * | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| CN109528761A (zh) * | 2018-12-20 | 2019-03-29 | 江西润泽药业有限公司 | 制备钠钾钙镁葡萄糖注射液的方法 |
| JP2023517926A (ja) | 2020-03-12 | 2023-04-27 | バクスター・インターナショナル・インコーポレイテッド | ソルビトールとマンニトールの組み合わせを含むダプトマイシン製剤 |
| IL304283B2 (en) * | 2020-03-31 | 2024-12-01 | 3 D Matrix Ltd | Sterilization of self-assembling peptides by irradiation |
| KR102869156B1 (ko) * | 2021-03-29 | 2025-10-15 | (주)아모레퍼시픽 | 콜라겐 펩티드 안정화용 조성물 및 이를 포함하는 식품 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| AUPO871997A0 (en) | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
| GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| JP2003055257A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第ｘｉｉｉ因子製剤 |
| US20030186891A1 (en) | 2002-02-08 | 2003-10-02 | Toshio Okano | Compositions and methods for treatment of vitamin D deficiency |
| AU2003268380A1 (en) * | 2002-10-04 | 2004-05-04 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| WO2006023665A2 (en) * | 2004-08-17 | 2006-03-02 | Regeneron Pharmaceuticals, Inc. | Il-1 antagonist formulations |
-
2008
- 2008-05-29 MX MX2009012964A patent/MX2009012964A/es active IP Right Grant
- 2008-05-29 JP JP2010510365A patent/JP2010530846A/ja active Pending
- 2008-05-29 EP EP08768001A patent/EP2150537A4/en not_active Withdrawn
- 2008-05-29 US US12/129,504 patent/US7879805B2/en not_active Expired - Fee Related
- 2008-05-29 WO PCT/US2008/006898 patent/WO2008150479A2/en not_active Ceased
- 2008-05-29 CA CA002687246A patent/CA2687246A1/en not_active Abandoned
- 2008-05-29 AU AU2008260483A patent/AU2008260483A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008260483A1 (en) | 2008-12-11 |
| EP2150537A4 (en) | 2010-09-22 |
| WO2008150479A2 (en) | 2008-12-11 |
| CA2687246A1 (en) | 2008-12-11 |
| US7879805B2 (en) | 2011-02-01 |
| EP2150537A2 (en) | 2010-02-10 |
| US20090054331A1 (en) | 2009-02-26 |
| WO2008150479A3 (en) | 2009-02-19 |
| JP2010530846A (ja) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012964A (es) | Formulacion de peptido estable a alta temperatura. | |
| JP6239167B2 (ja) | リポペプチド組成物および関連する方法 | |
| MY197773A (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| EP3169313B1 (en) | A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof | |
| RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| ATE454137T1 (de) | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab | |
| TN2009000382A1 (en) | Stable antibody formulations | |
| JP4948410B2 (ja) | Ｉｌ−１アンタゴニスト製剤 | |
| ES2403121T3 (es) | Formulación de paracetamol inyectable, estable, lista para usar | |
| JPWO2008020584A1 (ja) | 安定な凍結乾燥製剤 | |
| KR20160048227A (ko) | 고나도트로핀을 위한 제제 | |
| JP2011516461A (ja) | 液体配合物及び凍結乾燥した配合物 | |
| CN103037848A (zh) | 氟吡汀的可注射剂型 | |
| NZ733837B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
| HK1236813A1 (en) | A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |